How is acute promyelocytic leukemia (APL) treated in elderly patients?

Updated: Jul 02, 2019
  • Author: Sandy D Kotiah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Elderly patients (> 60y) have poorer outcomes with standard treatment; in the PETHEMA trial, the last dose of idarubicin was omitted during induction; consolidation should be altered to liposomal ATRA and ATO [14]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!